免疫检查点抑制剂治疗进展后,再次使用是否有效?
anti-CTLA-4→anti-PD-1
anti-PD-1→anti- CTLA-4
anti- CTLA-4→anti- CTLA-4
由于毒性或临床决策停用初始ICI 初始ICI治疗持续时间>3个月
1. E Gobbini, J Charles, AC Toffart, et al. Currentopinions in immune checkpoint inhibitors rechallenge in solid cancers. Crit RevOncol Hematol. 2019; 144: 102816.
2. Gobbini, et al. MA07.05, 2019 WCLC.
3. GL Matteo, et al. Immunotherapy rechallenge afternivolumab treatment in advanced non-small cell lung cancer in the real-worldsetting: A national data base analysis. Lung Cancer. 2020;140: 99-106.
4. Kitagawa S, Hakozaki T,Kitadai R, et al. Switching administration of anti-PD-1 and anti-PD-L1antibodies as immune checkpoint inhibitor rechallenge in individuals withadvanced non-small cell lung cancer: Case series and literature review. ThoracCancer. 2020 Jul;11(7):1927-1933.
5. Ravi P, Mantia C, Christopher S, et al. Evaluationof the Safety and Efficacy of Immunotherapy Rechallenge in Patients With RenalCell Carcinoma. JAMA Oncol. 2020; e202169.
精彩推荐:
- End -